Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLT-A2
- Development stage
- Preclinical
- Lead developer
- MediPrint Ophthalmics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
LLT-A2 is a preclinical-stage drug-eluting contact lens being developed by **MediPrint Ophthalmics** for the treatment of **ocular allergy**. The product utilizes the company's proprietary **MediPrint™** 3D printing technology to incorporate an active pharmaceutical ingredient—likely an antihistamine or mast cell stabilizer—directly into a contact lens. This platform is designed to provide sustained, continuous release of medication to the ocular surface, aiming to improve therapeutic outcomes and patient compliance compared to traditional topical eye drops, which are often limited by rapid tear washout and poor adherence.
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on LLT-A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLT-A2.